ECNP-PsychX talks
Bringing you the latest science in psychiatry
About PsychX and ECNP
We believe in making mental health expertise readily available to all. This vision led to the creation of PsychX, a platform to champion both emerging and established voices in the mental health domain. Every month, we host short online discussions spanning various mental health topics, making knowledge accessible without registration fees or hidden costs.
Join these high-relevance free online sessions, featuring monthly explorations into both clinical and experimental facets of psychiatry.
In 2022, PsychX and ECNP started collaborating. As from 2023, all PsychX talks were transferred to ECNP.
How to join the talks
You can register for these talks here.
Upcoming talks
Mark your calendars for our lineup!
3 February 2025, 16.30 CET
Koen Schruers, The Netherlands
Title of the talk, bio and outline to be announced.
3 March 2025, 16.30 CET
Real-world effectiveness of psychopharmacological treatments: recent insights
Jari Tiihonen, Sweden and Finland
Recent evidence has shown that in schizophrenia, only 10–20% of atypical patients are selected for RCTs investigating the efficacy of antipsychotic treatment. Therefore, the generalizability of RCTs to real-world patient population can be questioned. In addition, in RCTs, it is practically impossible to study the risk of death or rare severe side effects related to specific medication. This presentation will inform how large nation-wide registers can be used to study these issues.
Finland and Sweden have unique person identification number for each individual that enables linking of data on filled prescriptions in pharmacies, hospital admissions, work disability benefits, and mortality. This presentation will review methodological issues related to RCTs versus observational studies and show results on real-world effectiveness of specific psychotropic medications related to risk of relapse, work disability, and death among patients with non-affective psychosis, bipolar disorder, substance use disorder, and personality disorders.
Biography
Jari is professor at the department of clinical neuroscience in Karolinska Institutet, Stockholm, Sweden, and also professor and Chairman at the University of Eastern Finland, department of forensic psychiatry, Kuopio, Finland. The main topics in his scientific work in psychiatry are psychopharmacology, stem cell studies to elucidate neurobiology of schizophrenia, functional brain imaging, autoradiography studies on dopamine and serotonin receptors and transporters in the human brain, and epidemiology, genetics and neurobiology of schizophrenia, substance dependence, and violent and suicidal behavior. His H-index is 77.
Jari has developed pharmacoepidemiological methodology to study real-world effectiveness of psychopharmacological treatments by using nation-wide databases, and he has also conducted several randomised controlled trials on treatment-resistant schizophrenia and substance dependence.
7 April 2025, 16.30 CEST
Wolfgang Fleischhacker, Austria
Title of the talk, bio and outline to be announced.
5 May 2025, 16.30 CEST
Michael Ziller, Germany
Title of the talk, bio and outline to be announced.
2 June 2025, 16.30 CEST
Julio Licinio, USA
Julio Licinio’s presentation offers insights on publishing research in top scientific journals, based on his experience as editor of molecular psychiatry, translational psychiatry, and genomic press. He discusses strategies for manuscript preparation, submission, and revision, covering topics such as peer review handling, manuscript structuring, writing abstracts and methods sections, and responding to reviewers. The talk provides practical advice on positioning research for maximum impact, especially for early-career scientists aiming to publish in high-impact journals.
Julio, MD, PhD, MBA, MS, is a SUNY distinguished professor at SUNY Upstate Medical University in Syracuse, leading an NIH-funded research program on stress and related disorders. He has secured over $30 million in grants and published over 400 papers with 45,000 citations. He founded four Springer Nature journals, including Molecular Psychiatry and Translational Psychiatry, and is CEO of Genomic Press. He has held leadership roles at UCLA, University of Miami, Australian National University, and SUNY Upstate. He is a fellow of multiple prestigious organisations.
PsychX Programme Committee
Visit this page to find out about the PsychX Programme Committee and its members, goals, composition and time commitment.
Previous talks
View here previous PsychX talks.
